Review



3d interactive microscopy visualization software  (Oxford Instruments)


Bioz Verified Symbol Oxford Instruments is a verified supplier
Bioz Manufacturer Symbol Oxford Instruments manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    Oxford Instruments 3d interactive microscopy visualization software
    ( A ) <t>3D</t> surface projection of IHCs and OHCs from the cochlear 32 kHz region of Clic5 +/− , Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red) and actin (gray). ( B ) Representative confocal images of IHCs from the apical turn of Clic5 +/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red), actin (gray), and FLAG tag (green). ( C ) Representative confocal images of IHCs and OHCs from the cochlear 8 kHz region of Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with actin. ( D ) Stereocilia length measurements of IHC at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( E ) Quantification of OHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( F ) Quantification of IHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( G ) High-magnification scanning electron <t>microscopy</t> images of outer and inner hair bundles from the cochlea middle-turn of the Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks. ( H ) Representative images of IHCs and OHCs at 12 weeks at different regions of the cochlea of Clic5 −/ − injected with scAAV. Clic5 . ( I ) ABR thresholds at 4 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( J ) ABR thresholds at 8 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 11), and Clic5 −/− injected with scAVV. Clic5 (n = 7). ( K ) ABR thresholds at 12 weeks of Clic5 +/− ( n = 10), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 7). ( L ) DPOAE thresholds at 4 weeks of Clic5 +/− ( n = 12), Clic5 −/ − ( n = 12), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( M ) ABR thresholds at 3-time points of Clic5 −/− injected with scAAV. Clic5: 4 weeks ( n = 10), 8 weeks ( n = 7), and 12 weeks ( n = 7). ( N ) Freezing behavior duration in a fear conditioning assay at 12 weeks of Clic5 +/− ( n = 14), Clic5 − /− ( n = 14), and Clic5 −/− injected with scAAV. Clic5 ( n = 6). ( O ) Expression rates of scAAV. Clic5 across the cochlea as a function of viral titer, n = 3 for each group. ( P ) ABR thresholds at 4 weeks of Clic5 −/ − injected with scAAV .Clic5 at different viral doses: 1.52 × 10¹³ gc/ml ( n = 10), 1.52 × 10 12 gc/ml ( n = 3) and 1.52 × 10 11 gc/ml ( n = 3). Data information: Statistical tests were two-way ANOVA with Holm–Sidak correction for multiple comparisons for ( D – F , I – N , P ), and one-way ANOVA followed by Tukey correction for multiple comparisons for ( O ). Plots show mean ± SD. ns not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (Exact P values are provided in Appendix Table S ). Scale bars = 10 μm for ( A , C , H ), 2 μm for ( B ), 0.5 μm for OHC ( G ), and 2 μm for IHC ( G ). .
    3d Interactive Microscopy Visualization Software, supplied by Oxford Instruments, used in various techniques. Bioz Stars score: 99/100, based on 43596 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3d+interactive+visualization/pmc12423326-40-1-0?v=Oxford+Instruments
    Average 99 stars, based on 43596 article reviews
    3d interactive microscopy visualization software - by Bioz Stars, 2026-07
    99/100 stars

    Images

    1) Product Images from "AAV gene therapy rescues hearing and balance in a model of CLIC5 deafness"

    Article Title: AAV gene therapy rescues hearing and balance in a model of CLIC5 deafness

    Journal: EMBO Molecular Medicine

    doi: 10.1038/s44321-025-00275-7

    ( A ) 3D surface projection of IHCs and OHCs from the cochlear 32 kHz region of Clic5 +/− , Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red) and actin (gray). ( B ) Representative confocal images of IHCs from the apical turn of Clic5 +/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red), actin (gray), and FLAG tag (green). ( C ) Representative confocal images of IHCs and OHCs from the cochlear 8 kHz region of Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with actin. ( D ) Stereocilia length measurements of IHC at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( E ) Quantification of OHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( F ) Quantification of IHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( G ) High-magnification scanning electron microscopy images of outer and inner hair bundles from the cochlea middle-turn of the Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks. ( H ) Representative images of IHCs and OHCs at 12 weeks at different regions of the cochlea of Clic5 −/ − injected with scAAV. Clic5 . ( I ) ABR thresholds at 4 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( J ) ABR thresholds at 8 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 11), and Clic5 −/− injected with scAVV. Clic5 (n = 7). ( K ) ABR thresholds at 12 weeks of Clic5 +/− ( n = 10), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 7). ( L ) DPOAE thresholds at 4 weeks of Clic5 +/− ( n = 12), Clic5 −/ − ( n = 12), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( M ) ABR thresholds at 3-time points of Clic5 −/− injected with scAAV. Clic5: 4 weeks ( n = 10), 8 weeks ( n = 7), and 12 weeks ( n = 7). ( N ) Freezing behavior duration in a fear conditioning assay at 12 weeks of Clic5 +/− ( n = 14), Clic5 − /− ( n = 14), and Clic5 −/− injected with scAAV. Clic5 ( n = 6). ( O ) Expression rates of scAAV. Clic5 across the cochlea as a function of viral titer, n = 3 for each group. ( P ) ABR thresholds at 4 weeks of Clic5 −/ − injected with scAAV .Clic5 at different viral doses: 1.52 × 10¹³ gc/ml ( n = 10), 1.52 × 10 12 gc/ml ( n = 3) and 1.52 × 10 11 gc/ml ( n = 3). Data information: Statistical tests were two-way ANOVA with Holm–Sidak correction for multiple comparisons for ( D – F , I – N , P ), and one-way ANOVA followed by Tukey correction for multiple comparisons for ( O ). Plots show mean ± SD. ns not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (Exact P values are provided in Appendix Table S ). Scale bars = 10 μm for ( A , C , H ), 2 μm for ( B ), 0.5 μm for OHC ( G ), and 2 μm for IHC ( G ). .
    Figure Legend Snippet: ( A ) 3D surface projection of IHCs and OHCs from the cochlear 32 kHz region of Clic5 +/− , Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red) and actin (gray). ( B ) Representative confocal images of IHCs from the apical turn of Clic5 +/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red), actin (gray), and FLAG tag (green). ( C ) Representative confocal images of IHCs and OHCs from the cochlear 8 kHz region of Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with actin. ( D ) Stereocilia length measurements of IHC at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( E ) Quantification of OHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( F ) Quantification of IHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( G ) High-magnification scanning electron microscopy images of outer and inner hair bundles from the cochlea middle-turn of the Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks. ( H ) Representative images of IHCs and OHCs at 12 weeks at different regions of the cochlea of Clic5 −/ − injected with scAAV. Clic5 . ( I ) ABR thresholds at 4 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( J ) ABR thresholds at 8 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 11), and Clic5 −/− injected with scAVV. Clic5 (n = 7). ( K ) ABR thresholds at 12 weeks of Clic5 +/− ( n = 10), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 7). ( L ) DPOAE thresholds at 4 weeks of Clic5 +/− ( n = 12), Clic5 −/ − ( n = 12), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( M ) ABR thresholds at 3-time points of Clic5 −/− injected with scAAV. Clic5: 4 weeks ( n = 10), 8 weeks ( n = 7), and 12 weeks ( n = 7). ( N ) Freezing behavior duration in a fear conditioning assay at 12 weeks of Clic5 +/− ( n = 14), Clic5 − /− ( n = 14), and Clic5 −/− injected with scAAV. Clic5 ( n = 6). ( O ) Expression rates of scAAV. Clic5 across the cochlea as a function of viral titer, n = 3 for each group. ( P ) ABR thresholds at 4 weeks of Clic5 −/ − injected with scAAV .Clic5 at different viral doses: 1.52 × 10¹³ gc/ml ( n = 10), 1.52 × 10 12 gc/ml ( n = 3) and 1.52 × 10 11 gc/ml ( n = 3). Data information: Statistical tests were two-way ANOVA with Holm–Sidak correction for multiple comparisons for ( D – F , I – N , P ), and one-way ANOVA followed by Tukey correction for multiple comparisons for ( O ). Plots show mean ± SD. ns not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (Exact P values are provided in Appendix Table S ). Scale bars = 10 μm for ( A , C , H ), 2 μm for ( B ), 0.5 μm for OHC ( G ), and 2 μm for IHC ( G ). .

    Techniques Used: Injection, Staining, FLAG-tag, Electron Microscopy, Expressing



    Similar Products

    86
    Plotly Technologies Inc interactive 3d visualizations
    Interactive 3d Visualizations, supplied by Plotly Technologies Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3d+interactive+visualization/med_rxiv__64898__2026__04__27__26351743-152-4-8?v=Plotly+Technologies+Inc
    Average 86 stars, based on 1 article reviews
    interactive 3d visualizations - by Bioz Stars, 2026-07
    86/100 stars
      Buy from Supplier

    99
    Oxford Instruments 10 1 3d interactive microscopy visualization software
    10 1 3d Interactive Microscopy Visualization Software, supplied by Oxford Instruments, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3d+interactive+visualization/10__1038_slash_s44321___025___00275___7-246-16-15?v=Oxford+Instruments
    Average 99 stars, based on 1 article reviews
    10 1 3d interactive microscopy visualization software - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    99
    Oxford Instruments ma imaris 3d interactive microscopy visualization software oxford instruments
    Ma Imaris 3d Interactive Microscopy Visualization Software Oxford Instruments, supplied by Oxford Instruments, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3d+interactive+visualization/10__1038_slash_s44321___025___00275___7-206-137-138?v=Oxford+Instruments
    Average 99 stars, based on 1 article reviews
    ma imaris 3d interactive microscopy visualization software oxford instruments - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    99
    Oxford Instruments 3d interactive microscopy visualization software
    ( A ) <t>3D</t> surface projection of IHCs and OHCs from the cochlear 32 kHz region of Clic5 +/− , Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red) and actin (gray). ( B ) Representative confocal images of IHCs from the apical turn of Clic5 +/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red), actin (gray), and FLAG tag (green). ( C ) Representative confocal images of IHCs and OHCs from the cochlear 8 kHz region of Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with actin. ( D ) Stereocilia length measurements of IHC at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( E ) Quantification of OHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( F ) Quantification of IHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( G ) High-magnification scanning electron <t>microscopy</t> images of outer and inner hair bundles from the cochlea middle-turn of the Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks. ( H ) Representative images of IHCs and OHCs at 12 weeks at different regions of the cochlea of Clic5 −/ − injected with scAAV. Clic5 . ( I ) ABR thresholds at 4 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( J ) ABR thresholds at 8 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 11), and Clic5 −/− injected with scAVV. Clic5 (n = 7). ( K ) ABR thresholds at 12 weeks of Clic5 +/− ( n = 10), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 7). ( L ) DPOAE thresholds at 4 weeks of Clic5 +/− ( n = 12), Clic5 −/ − ( n = 12), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( M ) ABR thresholds at 3-time points of Clic5 −/− injected with scAAV. Clic5: 4 weeks ( n = 10), 8 weeks ( n = 7), and 12 weeks ( n = 7). ( N ) Freezing behavior duration in a fear conditioning assay at 12 weeks of Clic5 +/− ( n = 14), Clic5 − /− ( n = 14), and Clic5 −/− injected with scAAV. Clic5 ( n = 6). ( O ) Expression rates of scAAV. Clic5 across the cochlea as a function of viral titer, n = 3 for each group. ( P ) ABR thresholds at 4 weeks of Clic5 −/ − injected with scAAV .Clic5 at different viral doses: 1.52 × 10¹³ gc/ml ( n = 10), 1.52 × 10 12 gc/ml ( n = 3) and 1.52 × 10 11 gc/ml ( n = 3). Data information: Statistical tests were two-way ANOVA with Holm–Sidak correction for multiple comparisons for ( D – F , I – N , P ), and one-way ANOVA followed by Tukey correction for multiple comparisons for ( O ). Plots show mean ± SD. ns not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (Exact P values are provided in Appendix Table S ). Scale bars = 10 μm for ( A , C , H ), 2 μm for ( B ), 0.5 μm for OHC ( G ), and 2 μm for IHC ( G ). .
    3d Interactive Microscopy Visualization Software, supplied by Oxford Instruments, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3d+interactive+visualization/pmc12423326-40-1-0?v=Oxford+Instruments
    Average 99 stars, based on 1 article reviews
    3d interactive microscopy visualization software - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    90
    Plotly Technologies Inc 3d interactive visualization
    ( A ) <t>3D</t> surface projection of IHCs and OHCs from the cochlear 32 kHz region of Clic5 +/− , Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red) and actin (gray). ( B ) Representative confocal images of IHCs from the apical turn of Clic5 +/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red), actin (gray), and FLAG tag (green). ( C ) Representative confocal images of IHCs and OHCs from the cochlear 8 kHz region of Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with actin. ( D ) Stereocilia length measurements of IHC at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( E ) Quantification of OHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( F ) Quantification of IHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( G ) High-magnification scanning electron <t>microscopy</t> images of outer and inner hair bundles from the cochlea middle-turn of the Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks. ( H ) Representative images of IHCs and OHCs at 12 weeks at different regions of the cochlea of Clic5 −/ − injected with scAAV. Clic5 . ( I ) ABR thresholds at 4 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( J ) ABR thresholds at 8 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 11), and Clic5 −/− injected with scAVV. Clic5 (n = 7). ( K ) ABR thresholds at 12 weeks of Clic5 +/− ( n = 10), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 7). ( L ) DPOAE thresholds at 4 weeks of Clic5 +/− ( n = 12), Clic5 −/ − ( n = 12), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( M ) ABR thresholds at 3-time points of Clic5 −/− injected with scAAV. Clic5: 4 weeks ( n = 10), 8 weeks ( n = 7), and 12 weeks ( n = 7). ( N ) Freezing behavior duration in a fear conditioning assay at 12 weeks of Clic5 +/− ( n = 14), Clic5 − /− ( n = 14), and Clic5 −/− injected with scAAV. Clic5 ( n = 6). ( O ) Expression rates of scAAV. Clic5 across the cochlea as a function of viral titer, n = 3 for each group. ( P ) ABR thresholds at 4 weeks of Clic5 −/ − injected with scAAV .Clic5 at different viral doses: 1.52 × 10¹³ gc/ml ( n = 10), 1.52 × 10 12 gc/ml ( n = 3) and 1.52 × 10 11 gc/ml ( n = 3). Data information: Statistical tests were two-way ANOVA with Holm–Sidak correction for multiple comparisons for ( D – F , I – N , P ), and one-way ANOVA followed by Tukey correction for multiple comparisons for ( O ). Plots show mean ± SD. ns not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (Exact P values are provided in Appendix Table S ). Scale bars = 10 μm for ( A , C , H ), 2 μm for ( B ), 0.5 μm for OHC ( G ), and 2 μm for IHC ( G ). .
    3d Interactive Visualization, supplied by Plotly Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3d+interactive+visualization/10__1190_slash_geo2024___0041__1-87-5-15?v=Plotly+Technologies+Inc
    Average 90 stars, based on 1 article reviews
    3d interactive visualization - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Accelrys 2d and 3d interaction visualizations
    ( A ) <t>3D</t> surface projection of IHCs and OHCs from the cochlear 32 kHz region of Clic5 +/− , Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red) and actin (gray). ( B ) Representative confocal images of IHCs from the apical turn of Clic5 +/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red), actin (gray), and FLAG tag (green). ( C ) Representative confocal images of IHCs and OHCs from the cochlear 8 kHz region of Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with actin. ( D ) Stereocilia length measurements of IHC at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( E ) Quantification of OHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( F ) Quantification of IHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( G ) High-magnification scanning electron <t>microscopy</t> images of outer and inner hair bundles from the cochlea middle-turn of the Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks. ( H ) Representative images of IHCs and OHCs at 12 weeks at different regions of the cochlea of Clic5 −/ − injected with scAAV. Clic5 . ( I ) ABR thresholds at 4 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( J ) ABR thresholds at 8 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 11), and Clic5 −/− injected with scAVV. Clic5 (n = 7). ( K ) ABR thresholds at 12 weeks of Clic5 +/− ( n = 10), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 7). ( L ) DPOAE thresholds at 4 weeks of Clic5 +/− ( n = 12), Clic5 −/ − ( n = 12), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( M ) ABR thresholds at 3-time points of Clic5 −/− injected with scAAV. Clic5: 4 weeks ( n = 10), 8 weeks ( n = 7), and 12 weeks ( n = 7). ( N ) Freezing behavior duration in a fear conditioning assay at 12 weeks of Clic5 +/− ( n = 14), Clic5 − /− ( n = 14), and Clic5 −/− injected with scAAV. Clic5 ( n = 6). ( O ) Expression rates of scAAV. Clic5 across the cochlea as a function of viral titer, n = 3 for each group. ( P ) ABR thresholds at 4 weeks of Clic5 −/ − injected with scAAV .Clic5 at different viral doses: 1.52 × 10¹³ gc/ml ( n = 10), 1.52 × 10 12 gc/ml ( n = 3) and 1.52 × 10 11 gc/ml ( n = 3). Data information: Statistical tests were two-way ANOVA with Holm–Sidak correction for multiple comparisons for ( D – F , I – N , P ), and one-way ANOVA followed by Tukey correction for multiple comparisons for ( O ). Plots show mean ± SD. ns not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (Exact P values are provided in Appendix Table S ). Scale bars = 10 μm for ( A , C , H ), 2 μm for ( B ), 0.5 μm for OHC ( G ), and 2 μm for IHC ( G ). .
    2d And 3d Interaction Visualizations, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3d+interactive+visualization/pm39500041-84-1-9?v=Accelrys
    Average 90 stars, based on 1 article reviews
    2d and 3d interaction visualizations - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Accelrys 3d molecular interactions visualized using biovia discovery studio visualizer v24.1.0.23298
    ( A ) <t>3D</t> surface projection of IHCs and OHCs from the cochlear 32 kHz region of Clic5 +/− , Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red) and actin (gray). ( B ) Representative confocal images of IHCs from the apical turn of Clic5 +/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red), actin (gray), and FLAG tag (green). ( C ) Representative confocal images of IHCs and OHCs from the cochlear 8 kHz region of Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with actin. ( D ) Stereocilia length measurements of IHC at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( E ) Quantification of OHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( F ) Quantification of IHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( G ) High-magnification scanning electron <t>microscopy</t> images of outer and inner hair bundles from the cochlea middle-turn of the Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks. ( H ) Representative images of IHCs and OHCs at 12 weeks at different regions of the cochlea of Clic5 −/ − injected with scAAV. Clic5 . ( I ) ABR thresholds at 4 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( J ) ABR thresholds at 8 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 11), and Clic5 −/− injected with scAVV. Clic5 (n = 7). ( K ) ABR thresholds at 12 weeks of Clic5 +/− ( n = 10), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 7). ( L ) DPOAE thresholds at 4 weeks of Clic5 +/− ( n = 12), Clic5 −/ − ( n = 12), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( M ) ABR thresholds at 3-time points of Clic5 −/− injected with scAAV. Clic5: 4 weeks ( n = 10), 8 weeks ( n = 7), and 12 weeks ( n = 7). ( N ) Freezing behavior duration in a fear conditioning assay at 12 weeks of Clic5 +/− ( n = 14), Clic5 − /− ( n = 14), and Clic5 −/− injected with scAAV. Clic5 ( n = 6). ( O ) Expression rates of scAAV. Clic5 across the cochlea as a function of viral titer, n = 3 for each group. ( P ) ABR thresholds at 4 weeks of Clic5 −/ − injected with scAAV .Clic5 at different viral doses: 1.52 × 10¹³ gc/ml ( n = 10), 1.52 × 10 12 gc/ml ( n = 3) and 1.52 × 10 11 gc/ml ( n = 3). Data information: Statistical tests were two-way ANOVA with Holm–Sidak correction for multiple comparisons for ( D – F , I – N , P ), and one-way ANOVA followed by Tukey correction for multiple comparisons for ( O ). Plots show mean ± SD. ns not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (Exact P values are provided in Appendix Table S ). Scale bars = 10 μm for ( A , C , H ), 2 μm for ( B ), 0.5 μm for OHC ( G ), and 2 μm for IHC ( G ). .
    3d Molecular Interactions Visualized Using Biovia Discovery Studio Visualizer V24.1.0.23298, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3d+interactive+visualization/pm39520616-283-1-8?v=Accelrys
    Average 90 stars, based on 1 article reviews
    3d molecular interactions visualized using biovia discovery studio visualizer v24.1.0.23298 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) 3D surface projection of IHCs and OHCs from the cochlear 32 kHz region of Clic5 +/− , Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red) and actin (gray). ( B ) Representative confocal images of IHCs from the apical turn of Clic5 +/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red), actin (gray), and FLAG tag (green). ( C ) Representative confocal images of IHCs and OHCs from the cochlear 8 kHz region of Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with actin. ( D ) Stereocilia length measurements of IHC at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( E ) Quantification of OHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( F ) Quantification of IHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( G ) High-magnification scanning electron microscopy images of outer and inner hair bundles from the cochlea middle-turn of the Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks. ( H ) Representative images of IHCs and OHCs at 12 weeks at different regions of the cochlea of Clic5 −/ − injected with scAAV. Clic5 . ( I ) ABR thresholds at 4 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( J ) ABR thresholds at 8 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 11), and Clic5 −/− injected with scAVV. Clic5 (n = 7). ( K ) ABR thresholds at 12 weeks of Clic5 +/− ( n = 10), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 7). ( L ) DPOAE thresholds at 4 weeks of Clic5 +/− ( n = 12), Clic5 −/ − ( n = 12), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( M ) ABR thresholds at 3-time points of Clic5 −/− injected with scAAV. Clic5: 4 weeks ( n = 10), 8 weeks ( n = 7), and 12 weeks ( n = 7). ( N ) Freezing behavior duration in a fear conditioning assay at 12 weeks of Clic5 +/− ( n = 14), Clic5 − /− ( n = 14), and Clic5 −/− injected with scAAV. Clic5 ( n = 6). ( O ) Expression rates of scAAV. Clic5 across the cochlea as a function of viral titer, n = 3 for each group. ( P ) ABR thresholds at 4 weeks of Clic5 −/ − injected with scAAV .Clic5 at different viral doses: 1.52 × 10¹³ gc/ml ( n = 10), 1.52 × 10 12 gc/ml ( n = 3) and 1.52 × 10 11 gc/ml ( n = 3). Data information: Statistical tests were two-way ANOVA with Holm–Sidak correction for multiple comparisons for ( D – F , I – N , P ), and one-way ANOVA followed by Tukey correction for multiple comparisons for ( O ). Plots show mean ± SD. ns not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (Exact P values are provided in Appendix Table S ). Scale bars = 10 μm for ( A , C , H ), 2 μm for ( B ), 0.5 μm for OHC ( G ), and 2 μm for IHC ( G ). .

    Journal: EMBO Molecular Medicine

    Article Title: AAV gene therapy rescues hearing and balance in a model of CLIC5 deafness

    doi: 10.1038/s44321-025-00275-7

    Figure Lengend Snippet: ( A ) 3D surface projection of IHCs and OHCs from the cochlear 32 kHz region of Clic5 +/− , Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red) and actin (gray). ( B ) Representative confocal images of IHCs from the apical turn of Clic5 +/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with a CLIC5 (red), actin (gray), and FLAG tag (green). ( C ) Representative confocal images of IHCs and OHCs from the cochlear 8 kHz region of Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 at 12 weeks, stained with actin. ( D ) Stereocilia length measurements of IHC at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( E ) Quantification of OHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( F ) Quantification of IHC survival at different regions of the cochlea, n = 3 for Clic5 +/− , Clic5 −/− , and Clic5 −/− injected with scAAV. Clic5 . ( G ) High-magnification scanning electron microscopy images of outer and inner hair bundles from the cochlea middle-turn of the Clic5 −/− and Clic5 −/− injected with scAAV. Clic5 at 12 weeks. ( H ) Representative images of IHCs and OHCs at 12 weeks at different regions of the cochlea of Clic5 −/ − injected with scAAV. Clic5 . ( I ) ABR thresholds at 4 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( J ) ABR thresholds at 8 weeks of Clic5 +/− ( n = 11), Clic5 −/− ( n = 11), and Clic5 −/− injected with scAVV. Clic5 (n = 7). ( K ) ABR thresholds at 12 weeks of Clic5 +/− ( n = 10), Clic5 −/− ( n = 10), and Clic5 −/− injected with scAAV. Clic5 ( n = 7). ( L ) DPOAE thresholds at 4 weeks of Clic5 +/− ( n = 12), Clic5 −/ − ( n = 12), and Clic5 −/− injected with scAAV. Clic5 ( n = 10). ( M ) ABR thresholds at 3-time points of Clic5 −/− injected with scAAV. Clic5: 4 weeks ( n = 10), 8 weeks ( n = 7), and 12 weeks ( n = 7). ( N ) Freezing behavior duration in a fear conditioning assay at 12 weeks of Clic5 +/− ( n = 14), Clic5 − /− ( n = 14), and Clic5 −/− injected with scAAV. Clic5 ( n = 6). ( O ) Expression rates of scAAV. Clic5 across the cochlea as a function of viral titer, n = 3 for each group. ( P ) ABR thresholds at 4 weeks of Clic5 −/ − injected with scAAV .Clic5 at different viral doses: 1.52 × 10¹³ gc/ml ( n = 10), 1.52 × 10 12 gc/ml ( n = 3) and 1.52 × 10 11 gc/ml ( n = 3). Data information: Statistical tests were two-way ANOVA with Holm–Sidak correction for multiple comparisons for ( D – F , I – N , P ), and one-way ANOVA followed by Tukey correction for multiple comparisons for ( O ). Plots show mean ± SD. ns not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (Exact P values are provided in Appendix Table S ). Scale bars = 10 μm for ( A , C , H ), 2 μm for ( B ), 0.5 μm for OHC ( G ), and 2 μm for IHC ( G ). .

    Article Snippet: Imaris 3D Interactive Microscopy Visualization software , Oxford Instruments . , version 10.1.

    Techniques: Injection, Staining, FLAG-tag, Electron Microscopy, Expressing